Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
Jun 18, 2008 7:30am EDT

Rigel to Present at Jefferies Healthcare Conference

Jun 12, 2008 7:30am EDT

Rigel Initiates Two Phase 2b Clinical Trials of R788 in Rheumatoid Arthritis

Jun 05, 2008 7:30am EDT

Rigel to Present at the Needham Biotechnology and Medical Technology Conference

Jun 03, 2008 6:00am EDT

Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL

Jun 02, 2008 5:10pm EDT

Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma

May 06, 2008 7:30am EDT

Rigel Announces First Quarter 2008 Financial Results

Mar 27, 2008 7:30am EDT

Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference

Mar 13, 2008 7:30am EDT

Rigel Announces Participation in Upcoming Investor and Partnering Conferences

Feb 26, 2008 7:30am EST

Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research

Feb 12, 2008 7:30am EST

Rigel Announces Fourth Quarter and Year End 2007 Financial Results

  • Previous
  • 1…
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • Next
RSS
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin